sur Adolore Biotherapeutics, Inc.
Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit
DELRAY BEACH, FL / ACCESSWIRE / October 2, 2024 / Adolore BioTherapeutics, a company focused on developing opioid-free treatments for chronic pain, announced today that Dr. Roy C. Levitt will present at the 18th Annual Pain Therapeutics Summit. The summit will take place on October 28-29, 2024 in Boston, MA.
Dr. Levitt, the founder and Chief Medical Officer of Adolore, will discuss the company's innovative CA8* chronic pain therapeutics. These therapies utilize disease-free, nontoxic replication-defective Herpes Simplex Virus (rdHSV) vectors for intracellular delivery. The company is progressing its lead programs, ADB-101 and ADB-102, towards investigational new drug filings and human clinical studies.
The development program for chronic pain due to knee osteoarthritis is supported by an NIH/NINDS HEAL UH3 Award, funding preclinical studies through to human trials expected to start in 2026.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Adolore Biotherapeutics, Inc.